Potential drug-drug interactions associated with prolonged stays in the intensive care unit: A retrospective cohort study

Clinical Drug Investigation

Volumn 31, Issue 5, 2011, Pages 309-316

  Moura, Cristiano ^a   Prado, Nlia ^b   Acurcio, Francisco ^c  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b Pediatric Intensive Care Unit of the General Hospital of Vitória da Conquista Bahia   (Brazil)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Drug interactions; Hospitalisation

Indexed keywords

ACETYLSALICYLIC ACID; AMIKACIN; AMINOPHYLLINE; AMIODARONE; CAPTOPRIL; CEFALOTIN; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; DEXAMETHASONE; DIGOXIN; FUROSEMIDE; GENTAMICIN; HEPARIN; HYDROCHLOROTHIAZIDE; HYDROCORTISONE; INSULIN; KETOPROFEN; OXACILLIN; PANCURONIUM BROMIDE; PHENYTOIN; PROPRANOLOL; SPIRONOLACTONE;

ADULT; AGED; ANTIMICROBIAL ACTIVITY; ARTICLE; BLEEDING; CONTROLLED STUDY; DIGESTIVE SYSTEM ULCER; DRUG BLOOD LEVEL; DRUG EFFECT; FATIGUE; FEMALE; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HEALTH PROGRAM; HEART ARRHYTHMIA; HOSPITAL ADMISSION; HOSPITAL COST; HOSPITALIZATION; HUMAN; HYPOGLYCEMIA; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; POTASSIUM BLOOD LEVEL; PRESCRIPTION; PRIORITY JOURNAL; RESPIRATION DEPRESSION; RETROSPECTIVE STUDY; SIDE EFFECT; TOXICITY; WEAKNESS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAZIL; COHORT STUDIES; DRUG INTERACTIONS; FEMALE; HUMANS; INTENSIVE CARE UNITS; KAPLAN-MEIER ESTIMATE; LENGTH OF STAY; MALE; MEDICATION ERRORS; MIDDLE AGED; PHARMACEUTICAL PREPARATIONS; PROPORTIONAL HAZARDS MODELS; QUALITY INDICATORS, HEALTH CARE; QUALITY OF HEALTH CARE; RETROSPECTIVE STUDIES;

EID: 79953821256     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11586200-000000000-00000     Document Type: Article

References (23)

1. Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash) 2001 Mar-Apr; 41 (2): 192-9
2. Classen DC, Pestotnik SL, Evans RS, et al. Adverse drug events in hospitalized patients: excess length of stay, extra costs, and attributable mortality. JAMA 1997 Jan 22-29; 277 (4): 301-6 (Pubitemid 27045010)
3. Jankel CA, Speedie SM. Detecting drug interactions: a review of the literature. DICP 1990 Oct; 24 (10): 982-9 (Pubitemid 20307253)
4. Heininger-Rothbucher D, Bischinger S, Ulmer H, et al. Incidence and risk of potential adverse drug interactions in the emergency room. Resuscitation 2001 Jun; 49 (3): 283-8 (Pubitemid 32588706)
5. Janchawee B, Wongpoowarak W, Owatranporn T, et al. Pharmacoepidemiologic study of potential drug interac-tions in outpatients of a university hospital in Thailand. J Clin Pharm Ther 2005 Feb; 30 (1): 13-20 (Pubitemid 41602088)
6. Cruciol-Souza JM, Thomson JC Prevalence of potential drug-drug interactions and its associated factors in a Brazilian teaching hospital. J Pharm Pharm Sci 2006; 9 (3): 427-33 (Pubitemid 46630111)
7. Glintborg B, Andersen SE, Dalhoff K. Drug-drug interactions among recently hospitalised patients: frequent but mostly clinically insignificant. Eur J Clin Pharmacol 2005 Oct; 61 (9): 675-81
8. Riechelmann RP, Zimmermann C, Chin SN, et al. Potential drug interactions in cancer patients receiving supportive care exclusively. J Pain Symptom Manage 2008 May; 35 (5): 535-43
9. Hammes JA, Pfuetzenreiter F, da Silveira F, et al. Potential drug interactions prevalence in intensive care units. Rev Bras Ter Intensiva 2008; 20 (4): 349-54
10. Tamblyn RM, McLeod PJ, Abrahamowicz M, et al. Do too many cooks spoil the broth? Multiple physician involve-ment in medical management of elderly patients and po-tentially inappropriate drug combinations. CMAJ 1996 Apr 15; 154 (8): 1177-84 (Pubitemid 26143694)
11. Egger SS, Ratz Bravo AE, Hess L, et al. Age-related differences in the prevalence ofpotential drug-drug interactions in ambulatory dyslipidaemic patients treated with statins. Drugs Aging 2007; 24 (5): 429-40 (Pubitemid 46795183)
12. Gagne JJ, Maio V, Rabinowitz C Prevalence and predictors of potential drug-drug interactions in Regione Emilia-Romagna, Italy. J Clin Pharm Ther 2008 Apr; 33 (2): 141-51 (Pubitemid 351341403)
13. World Health Organization (WHO). International classification of diseases. 10th rev. ed. WHO: Geneva, 1994
14. Ramiarina RA, Ramiarina BL, Almeida RM, et al. Comorbidity adjustment index for the International Classifi-cation of Diseases, 10th rev. Rev Saude Publica 2008 Aug; 42 (4): 590-7
15. Portela MC, Schramm JM, Pepe VL, et al. Algorithm for establishing hospital admittance data based on the hospital information system in the Brazilian Unified Health System. Cad Saude Publica 1997 Oct; 13 (4): 771-4
16. Tatro D. Drug interaction facts 2007: facts and comparisons. St Louis (MO): Wolters Kluwer Health Inc., 2007
17. Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics 1982 Mar; 38: 29-41
18. Vargas E, Simon J, Martin JC, et al. Effect of adverse drug reactions on length of stay in intensive care units. Clin Drug Investig 1998; 15 (4): 353-60 (Pubitemid 28204009)
19. Sierra P, Castillo J, Gomez M, et al. Potential and real drug interactions in critical care patients. Rev Esp Anestesiol Reanim 1997 Dec; 44 (10): 383-7 (Pubitemid 28057012)
20. Knaus WA, Draper EA, Wagner DP, et al. APACHE II: a severity of disease classification system. Crit Care Med 1985 Oct; 13 (10): 818-29 (Pubitemid 15250137)
21. Lemeshow S, Le Gall JR. Modeling the severity of illness of ICU patients: a systems update. JAMA 1994 Oct 5; 272 (13): 1049-55 (Pubitemid 24294657)
22. Schneitman-McIntire O, Farnen TA, Gordon N, et al. Medication misadventures resulting in emergency depart-ment visits at an HMO medical center. Am J Health Syst Pharm 1996 Jun 15; 53 (12): 1416-22 (Pubitemid 26186031)
23. McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharma-cother 2002 Sep; 36 (9): 1331-6 (Pubitemid 34925265)